CoChat

Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy

Open access
Brown, Rebecca J., Valencia, Areli, Startzell, Megan, Cochran, Elaine, Walter, Peter J., Garraffo, H. Martin, Cai, Hongyi, Gharib, Ahmed M., Ouwerkerk, Ronald, Courville, Amber B., Bernstein, Shanna, Brychta, Robert J., Chen, Kong Y., Walter, Mary, Auh, Sungyoung, Gorden, Phillip · 2018 · Journal of Clinical Investigation
Cited by 99

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Recombinant leptin (metreleptin) ameliorates hyperphagia and metabolic abnormalities in leptin-deficient humans with lipodystrophy. We aimed to determine whether metreleptin improves glucose and lipid metabolism in humans when food intake is held constant. METHODS: Patients with lipodystrophy were hospitalized for 19 days, with food intake held constant by a controlled diet in an inpatient metabolic ward. In a nonrandomized, crossover design, patients previously treated with metreleptin (n = 8) were continued on metreleptin for 5 days and then taken off metreleptin for the next 14 days (withdrawal cohort). This order was reversed in metreleptin-naive patients (n = 14), who were reevaluated after 6 months of metreleptin treatment on an ad libitum diet (initiation cohort). Outcome measurements included insulin sensitivity by hyperinsulinemic-euglycemic clamp, fasting glucose and triglyceride levels, lipolysis measured using isotopic tracers, and liver fat by magnetic resonance spectroscopy. RESULTS: With food intake constant, peripheral insulin sensitivity decreased by 41% after stopping metreleptin for 14 days (withdrawal cohort) and increased by 32% after treatment with metreleptin for 14 days (initiation cohort). In the initiation cohort only, metreleptin decreased fasting glucose by 11% and triglycerides by 41% and increased hepatic insulin sensitivity. Liver fat decreased from 21.8% to 18.7%. In the initiation cohort, changes in lipolysis were not independent of food intake, but after 6 months of metreleptin treatment on an ad libitum diet, lipolysis decreased by 30% (palmitate turnover) to 35% (glycerol turnover). CONCLUSION: Using lipodystrophy as a human model of leptin deficiency and replacement, we show that metreleptin improves insulin sensitivity and decreases hepatic and circulating triglycerides and that these improvements are independent of its effects on food intake. TRIAL REGISTRATION: ClinicalTrials.gov NCT01778556FUNDING. This research was supported by the intramural research program of the NIDDK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci95476

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 99

Metadata

Authors
Brown, R. J., Valencia, A., Startzell, M., Cochran, E., Walter, P. J., Garraffo, H. M., Cai, H., Gharib, A. M., Ouwerkerk, R., Courville, A. B., Bernstein, S., Brychta, R. J., Chen, K. Y., Walter, M., Auh, S., & Gorden, P.
Venue
Journal of Clinical Investigation
Published
2018-07-16
Volume
128
Issue
8
Pages
3504-3516
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2799869022
Cited by
99
References
18
FWCI
6.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. https://app.cochat.ai/papers/10.1172/jci95476
The paper
Brown, R. J., Valencia, A., Startzell, M., Cochran, E., Walter, P. J., Garraffo, H. M., Cai, H., Gharib, A. M., Ouwerkerk, R., Courville, A. B., Bernstein, S., Brychta, R. J., Chen, K. Y., Walter, M., Auh, S., & Gorden, P. (2018). Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. Journal of Clinical Investigation. https://doi.org/10.1172/jci95476

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.